

A Brief Guide on Pediatric Hematology

Shamma AlZaabi, Abdul-Kader Souid*

Department of Pediatrics, College of Medicine and Health Sciences - UAE University, Alain City, United Arab Emirates

***Corresponding Author:** Abdul-Kader Souid, Department of Pediatrics, College of Medicine and Health Sciences - UAE University, Alain City, United Arab Emirates.

Received date: October 27, 2023; **Accepted date:** November 01, 2023; **Published date:** November 06, 2023

Citation: Shamma AlZaabi, Abdul-Kader Souid, (2023), A Brief Guide on Pediatric Hematology, *Archives of Medical Case Reports and Case Study*, 7(5); DOI:10.31579/2692-9392/187

Copyright: © 2023, Abdul-Kader Souid. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Reference ('normal') values of the complete blood count (CBC) vary with age and gender. Hematocrit, mean cell hemoglobin (MCH) and mean cell hemoglobin concentration (MCHC) are calculated quantities and have limited clinical use. Moreover, the white blood cell (WBC) count, the sum of the more important differential counts, has also limited clinical use.

Key words: diabetes case reports; drug design and development; emergency medicine; ethical issues

Introduction

Reference ('normal') values of the complete blood count (CBC) vary with age and gender. Hematocrit, mean cell hemoglobin (MCH) and mean cell hemoglobin concentration (MCHC) are calculated quantities and have limited clinical use. Moreover, the white blood cell (WBC) count, the sum of the more important differential counts, has also limited clinical use. Percentage counts are not needed [1].

Proper clinical interpretation of the neutrophil, lymphocyte, monocyte, eosinophil, and basophil counts is essential. For example, a consistent neutrophil or lymphocyte count of $<1.0 \times 10^9/L$ always signifies neutropenia or lymphopenia (T cell deficiency), respectively. Moreover, a normal differential count does not contain nucleated red cells, myelocyte or metamyelocyte ('left shift'). A normal platelet count is 150 to $400 \times 10^9/L$; values $<150 \times 10^9/L$ are thrombocytopenia and $>400 \times 10^9/L$ are thrombocytosis (most commonly reactive).

Hemoglobin concentration. Normal hemoglobin concentration varies with age. Higher values occur in the newborn and in the adolescent male (Table 1). The low fetal arterial oxygen tension (PO_2) of ~30 mm Hg stimulates erythropoietin secretion, leading to secondary polycythemia. After birth, the rise in arterial PO_2 to ~90 mm Hg suppresses erythropoietin secretion, leading to a gradual decline in the red cell production that nadirs at ~2 months (physiologic anemia). This effect is steeper and occurs earlier in preterm neonates (with a typical hemoglobin concentration of 80 to 90 g/L by 1 to 2 months). Subsequently, a steady rise in hemoglobin concentration reaches maximum in post-pubertal males due to the effects of testosterone. The blood volume of a neonate increases by allowing emptying of placental vessels before cord clamping; a maximum delay in cord clamping of 60 seconds is recommended. Hemoglobin concentration is also influenced by the blood sampling technique; heel stick samples are less reliable than venous samples.

Birth	145
2 to 6 mo	90 (physiologic anemia)
4 to 12 y (pre-pubertal)	115
12-18 y (pubertal and post-pubertal males)	140
12-18 y (pubertal and post-pubertal females)	123

Red blood cells (RBC). The normal RBC count ranges from 3.5 to $6.5 \times 10^{12}/L$. About 1% to 2% of the circulating red cells are reticulocytes (immature non-nucleated red cells containing ribonucleic acid). Thus, the normal reticulocyte count ranges from 35 to $130 \times 10^9/L$; values $<35 \times 10^9/L$ are reticulocytopenia and $>130 \times 10^9/L$ reticulocytosis (Table 2). The nadir

of reticulocyte count occurs between one week and 2 months, which results in physiologic anemia; a high reticulocyte count during this period signifies hemolysis. Nucleated red cells are seen in the first week of life; their presence after one week signifies prenatal/ perinatal hypoxia, hemorrhage or hemolysis. After the newborn period, circulating nucleated red cells indicate

increased demand for production (e.g., hemorrhage or hemolysis) or bone marrow destruction (infiltration).

Birth	100 to 500 x10 ⁹ /L	3% to 7%
1 week to 2 mo	10 to 50 x10 ⁹ /L	0.1% to 1%
>2 mo	50 to 100 x10 ⁹ /L	1% to 2%

Mean cell volume (MCV). Red cell volume is expressed in femtoliter (fL = 10⁻¹⁵ L). Its value is determined using a calibrated electrical impedance (mean height of the voltage pulses generated during red cell counting). The red cells are macrocytic at birth, with MCV of 98 fL to 116 fL. MCV <94 fL at birth (cord blood sample) is microcytosis and signifies a-thalassemia trait (since b-thalassemia and iron deficiency anemia do not present at birth),

Table 3. After one month, MCV >98 fL indicates macrocytosis (e.g., B12 deficiency, which could be masked by a coexisting thalassemia trait, especially in a population with high prevalence of a-thalassemia trait). At one month of age, the lowest normal MCV is 70 fL. Thereafter, the lowest normal is “70 fL + y of age until 10 y”. Thus, MCV <70 fL is abnormal at any age.

Birth (cord blood)	98 to 116 fL
1 mo to 10 y	“70 fL + y of age” to 90 fL
>10 y	80 to 98 fL

Relative distribution width (RDW = ‘standard deviation ÷ MCV’ [unitless, expressed as percentage] is a measure of the variation of red cell volume (relative standard deviation, coefficient of variation, degree of spread/dispersion around the mean, anisocytosis). Normal RDW is <15% (or

<0.15). Iron deficiency anemia is usually associated with increased RDW, signifying a mixture of red cells of various sizes. RDW is the first parameter to become abnormal in iron deficiency anemia and the last to correct. A simplified report of the CBC is shown in Table 4.

Variables	Units
Hemoglobin	g/L
Red cells	x10 ¹² /L
Reticulocytes	x10 ⁹ /L
Standard deviation (SD) of red cell volume	fL
MCV	fL
RDW (SD of red cell volume ÷ MCV)	Unitless
Platelets	x10 ⁹ /L
Neutrophils	x10 ⁹ /L
Lymphocytes	x10 ⁹ /L
Monocytes	x10 ⁹ /L
Eosinophils	x10 ⁹ /L
Basophils	x10 ⁹ /L

II. Microcytic, Macrocytosis and Normocytic Anemias

Microcytosis (small red cells) signifies a decreased hemoglobin synthesis, usually due to iron deficiency (e.g., nutritional, milk-induced colitis, or hemorrhage), thalassemia trait (decreased a or b chain synthesis), chronic inflammation (blocks iron delivery to erythroid precursors), or [rarely] ineffective protoporphyrin

synthesis (e.g., hereditary sideroblastic anemia). Macrocytosis (large red cells), on the other hand, signifies impaired red cell production (e.g., adverse effect of a medication, B12 deficiency, or bone marrow failure syndrome). Normocytic (normal red cell size) hemolytic anemia is associated with jaundice, indirect hyperbilirubinemia, reticulocytosis, and splenomegaly. Examples include hemoglobinopathy (e.g., sickle cell disease), enzymopathy (e.g., glucose-6-phosphate dehydrogenase [G6PD]


deficiency), cytoskeletal (membrane) abnormality (e.g., hereditary spherocytosis), and autoimmune hemolytic anemia.

III. Disorders Related to Iron

Iron bioavailability requires: (1) Ferritin, (2) Transferrin, (3) Transferrin receptor, and (4) Iron-responsive element (IRE) binding protein (IRE-BP, an mRNA-binding protein that senses cellular iron). Ferritin sequesters cellular iron for prompt mobilization when needed. Transferrin carries iron in the plasma. Transferrin receptors bind and internalize the transferrin-iron complex. IRE-BP coordinates the production of ferritin and transferrin receptors. If cellular iron is low, IRE-BP binds to IRE in the 5' untranslated regions of mRNA, stimulating the translation of transferrin receptor and

inhibiting the translation of ferritin; thus, promoting iron uptake and decreasing iron storage. The opposite occur in iron overload.

The “divalent metal transport protein-1” (DMT-1) is found on the apical membrane of enterocytes (mainly in the duodenum and upper jejunum); it mediates cellular Fe^{2+} uptake. Iron then exists the cell via the transmembrane exporter *ferroportin*. Ferroportin is inhibited by hepcidin [2]. Of note, celiac disease should be considered in the diagnostic evaluation of children with iron deficiency [3-4]. Their oral iron is unlikely to be absorbed until the intestines recover (with the elimination of gluten). For these children, parenteral iron is recommended [5-6].



The gastric acid, ascorbic acid, citric acid (juices), lactose (sugars) reduce Fe^{3+} to Fe^{2+} , thus, increasing the bioavailability of dietary non-heme iron. Ascorbic acid also prevents binding of Fe^{3+} to plant phytates found in grains, such as oat, and rye, and polyphenols (e.g., tannins found in green tea, which binds iron and lowers its absorption).

Hepcidin, a critical regulator of iron bioavailability, is a hepatic hormone stimulated by iron and inflammation, and suppressed by iron deficiency, erythropoietin, hypoxia, and ineffective erythropoiesis [2]. Hepcidin inhibits iron absorption by binding to ferroportin and causing its internalization and degradation. Hepcidin also reduces iron efflux from macrophages and hepatocytes. Moreover, cytokines (e.g., lipopolysaccharide and interleukin-6) induce the release of hepatic hepcidin, resulting in iron sequestration in macrophages and ‘anemia of inflammation’. Low hepcidin, on the other hand, leads to increased iron absorption and export.

Absorbed Fe^{2+} is either stored as ferritin or exists the enterocyte through the basolateral membrane into the blood capillary; this transport is mediated by ferroportin (depicted in the shown schema). *Ferroportin* is present on the basolateral membrane and the membranes of macrophages, hepatocytes, and placenta. In the blood, transferrin binds exported iron and delivers it to the bone marrow and liver via the cell surface transferrin receptors.

Physiologic responses to iron deficiency include: (1) Low serum ferritin (levels $<12 \mu\text{g/L}$ indicate absent iron stores), (2) Low serum iron ($<40 \mu\text{g/dL}$), (3) Low transferrin saturation (the ratio of plasma iron to total iron-binding capacity [TIBC], which reflects iron supply to tissue; normal = $35\% \pm 15\%$; $<16\%$ is a criterion for iron-deficiency), (4) High soluble transferrin receptors (sTfR, normal = 5.5 mg/L), (5) High zinc protoporphyrin (zinc replaces iron on protoporphyrin; high levels are seen with inflammation, lead poisoning and sideroblastic anemia; normal value is $30 \mu\text{g/dL}$ ($0.53 \mu\text{mol/L}$),

which increases to $100 \mu\text{g/dL}$ [$1.78 \mu\text{mol/L}$] in iron deficiency), (6) Anemia (normocytic \rightarrow microcytic anemia), (7) High RDW, and (8) Reticulocytopenia [7-8]. It is important to note that serum ferritin, fasting serum iron, transferrin, and transferrin saturation are unreliable determinants of iron overload.

Inflammation and damages to ferritin-rich tissues (e.g., liver) elevate serum ferritin independent of iron stores. Serum ferritin is increased in inflammation; sTfR is not affected by inflammation; thus, sTfR is used to differentiate anemia of inflammation from iron deficiency.

MRI-based Ferriscan is a reliable indicator of liver iron. Children with thalassemia major require iron chelation when serum ferritin is $>1,000 \text{ ng/mL}$. MRI-based Ferriscan scan for liver iron quantitation is then requested at annual intervals to guide iron chelation. If the estimated liver iron is >15 to 25 mg Fe/g dry weight liver, MRI-based Ferriscan quantitation of cardiac iron should also be done. Chelation with one or two drugs should be utilized to maintain liver iron between 3 and 7 mg Fe/g dry weight liver and normal cardiac iron. Of note, liver iron (measured in a biopsy sample) is limited by the variable iron content throughout the liver (e.g., missing foci of hepatic fibrosis).

Transfusional iron (expressed in ‘mg iron per kg’) can be estimated as: ‘Total volume of transfused red cells (in mL) \times 0.6 (the average hematocrit in red cell bags) \times 0.8 to 1.0 mg (the amount of iron per mL of transfused red cells; as 0.8 to 1.0 mg iron is acquired for every mL of red cells transfused) \div patient weight (kg)’. Liver iron (expressed in ‘mg iron per g dry liver weight’) is estimated as: ‘Transfusional iron (mg/kg) \div 10.6 ’. Liver iron content of 15 to 20 mg/gram dry weight is associated with liver fibrosis. Chelation is recommended when liver iron is $>7 \text{ mg/g}$ dry weight liver.

Children with 'ineffective erythropoiesis', such as thalassemia intermedia should have their first liver Ferriscan at 10 y of age and

every year thereafter depending on the results. In the absence of any transfusion, their mean *annual* increase of hepatic iron typically is 0.38 ± 0.49 mg Fe/g dry weight liver, which is mediated by suppressed hepcidin, causing increased iron absorption. At this rate, iron accumulation leads to serious complications in young adults, such as hepatic fibrosis, cardiac dysfunction, renal tubular dysfunction, hypogonadism, diabetes, hypoparathyroidism, and infertility.

Haptoglobin (the primary hemoglobin-binding protein in plasma) and *hemopexin* (promotes detoxification of heme when haptoglobin is depleted) are responsible for intravascular iron salvages. Haptoglobin and hemopexin are acute phase reactants; their levels are increased in infection/inflammation. Both haptoglobin and hemopexin prevent free hemoglobin from being filtered through the kidney. Haptoglobin is the major hemoglobin-binding protein during intravascular hemolysis. Free hemoglobin binds to haptoglobin; while free heme binds to hemopexin. The heme-hemopexin complex is metabolized in the liver. The hemoglobin-haptoglobin complex (>150 kD) is internalized by CD163 (the monocyte-macrophage surface receptor) in 'red pulp' macrophages of the spleen and in Kupffer cells of the liver. The *CD163* gene is induced by glucocorticoids, increasing the clearance of hemoglobin-haptoglobin.

About 70% of the body iron is in heme (hemoglobin and myoglobin), 29% in ferritin or hemosiderin (storage forms of iron), and <1% in heme-containing enzymes (cytochromes, catalase, peroxidase) or in the plasma as transferrin. Daily iron loss is ~2 mg; mostly from sloughing in the gut, skin, and renal tubules; 6 µg iron per kg per day (<0.5 mg per day) is lost during normal menstruation.

An average diet contains two forms of iron: (1) Heme (10%, mainly Fe²⁺) and (2) Non-heme (90%, mainly Fe³⁺). Only 1-2 mg (10% of dietary iron) is absorbed daily. About 25% of heme iron (meat, poultry and fish) is absorbed, while only 5% non-heme iron (cereals, beans, and vegetables) is absorbed.

IV. Iron deficiency anemia (IDA)

Iron deficiency anemia (IDA) is common in early childhood. It is characterized by decreased hemoglobin, low MCV (microcytosis due to decreased hemoglobin synthesis), high RDW (heralds the production of

smaller red cells), and reticulocytopenia (iron-limiting erythropoiesis). Children between 6 mo and 3 y are especially susceptible due to inadequate dietary iron for their rapid growth. In the first 4-6 mo, most full-term infants have adequate iron transferred through the placenta during the last trimester of pregnancy. Thus, premature infants frequently develop iron deficiency. In infants, cow's milk induces colitis (gastrointestinal bleeding); thus, whole milk should not be introduced in the first year. The most conclusive evidence of iron deficiency anemia is iron-responsive anemia (iron-rich food [preferred as other micronutrient deficiencies are likely to coexist] with or without iron supplementation [depending on the severity]). Optimal response is obtained with 2 to 6 mg/kg/day of elemental iron; ferrous sulfate is the preferred form. The reticulocyte count increases in one week, followed by a gradual correction over 4 weeks. Treatment should continue for 3 mo [9-10].


Recommendations to prevent iron deficiency include iron supplement (1 to 2 mg/kg/day) to exclusive breast-fed infants after 4 mo; use of iron-fortified formulas (12 mg/L iron as ferrous sulfate) and cereals; iron supplement (2 to 3 mg/kg/day) for preterm infants after first mo; and delay cow's milk until after first year [9-10].

Iron deficiency may result in impaired growth, poor school achievement, delayed motor and cognitive development, impaired immune responses, hyperactivity, and socio-emotional problems. Lower scores in the Bayley Scales of Infant Development have been demonstrated at 9 to 12 mo between non-anemic, iron deficient, and iron-sufficient infants. Dietary supplements from early age is a public health solution to this common problem [11-12].

V. Thalassemia

(Greek: thalatta or thalassa = sea' –aima = blood; originating around the Mediterranean and Black Seas, hence the origin of the name, "Mediterranean Anemia")


These inherited disorders are characterized by decreased synthesis of the a- or b-chain. Synthesis of the a-chain peaks at 3 mo of fetal age and b-chain peaks at 3 mo after birth. Thus, a-thalassemia manifests at birth and b-thalassemia after 3 mo of life. Single gene copies of the b (hemoglobin-beta locus; *HBB*, MIM#141900), d (hemoglobin-delta locus; *HBD*, MIM#142000), g (hemoglobin, gamma A; *HBG1*, MIM#142200 and hemoglobin, gamma G; *HBG2*, MIM#142250), and epsilon (e) are mapped to each allele of chromosome 11 (as shown in the schema).



Two copies of the a gene (hemoglobin-alpha locus 1; *HBA1*, MIM#141800 and hemoglobin-alpha locus 2; *HBA2*, MIM#141850) are mapped to each allele of chromosome 16. Thus, a normal individual has four a genes. The four chains (a, b, g, and d) form the three normal hemoglobin variants (Table 5): (1) Hb A (93% to 97%, two a plus two b), (2) Hb A₂ (two a plus two d), and Hb F (two a plus two g). Since Hb A₂ and F do not contain b chain, b-

thalassemia trait is associated with higher percentages of A₂ and F. In a-thalassemia, the percentages of Hb A₂ and F remain normal. Thus, accurate determination of A₂ is crucial, as a slight (≥0.5%) elevation of A₂ signifies b-thalassemia trait. Children with b-thalassemia major (homozygous b-thalassemia, two defective b genes) have severe microcytic anemia and depend on blood transfusion. The variant either abolish (b⁰) or reduce (b⁺) b-chain synthesis.

A2	1-30 days = 0.0-2.1%; 1-2 mo = 0.0-2.6%; 3-5 mo = 1.3-3.1%; ≥ 6 mo = 2.0-3.3%.
F	1-30 days = 22.8-92.0%; 1-2 mo = 7.6-89.8%; 3-5 mo = 1.6-42.2%; 6-8 mo = 0.0-16.7%; 9-12 mo = 0.0-10.5%; 13-17 mo = 0.0-7.9%; 18-23 mo = 0.0-6.3%; ≥ 24 mo = 0.0-0.9%.



There are four α -thalassemia syndromes (see schema), as follows: (1) *Silent carrier* involves one deleted gene. These individuals have low-normal MCV or mild microcytosis (75 fL to 80 fL). (2) *α -Thalassemia trait* involves two deleted genes. These individuals have mild-to-moderate microcytosis (MCV <75 fL). There are two genetic forms of α -thalassemia trait. The *cis*-form involves two deleted genes, 'both on one allele'; this serious form is common in the Mediterranean population. The *trans*-form involves two deleted genes, 'one on each allele'; this benign form is common in the Arabian Peninsula. (3) *Hemoglobin H disease* involves three deleted genes (one parent has *cis*-form α -thalassemia trait [heterozygous α^0] and one has silent carrier). The unpaired b-chains form tetramers (b_4), termed "hemoglobin H" (not to be confused with hemoglobin H disease). The b_4 aggregates are more soluble than the a_4 aggregates. Thus, patients with hemoglobin H disease usually have only moderate-to-severe hemolytic anemia. (4) *Hydrous fetalis* involves four deleted genes (both parents have 'heterozygous α^0 '). The unpaired g-chains (g_4 , 'Bart's hemoglobin, a fast migrating variant') have high affinity to oxygen (bind oxygen tightly and release almost none to the fetal tissue), leading to hypoxia and hydrops (edema due to heart failure).

Bart's hemoglobin is elevated in all forms of α -thalassemia; it can be used to screen for neonatal α -thalassemia. Bart's Hemoglobin constitutes 1% to 2% in silent carrier, 2% to 10% in trait, 20% to 30% in hemoglobin H disease, and >80% in hydrops fetalis. As noted above, newborns with α -thalassemia trait have MCV <94 fL at birth, which also serves the diagnosis of α -thalassemia trait. Stem cell transplantation is curative for thalassemia major.

VI. Chronic transfusion

Complications of chronic transfusions include iron overload, alloimmunization, and viral infections. Accumulation of iron results in diabetes and hypopituitarism (hypogonadotropic hypogonadism, impaired fertility, osteopenia, and osteoporosis). Cardiomyopathy and arrhythmias are the leading causes to death. The same risk for hypogonadism exists with stem cell transplantation and is caused by previous iron overload and the conditioning regimen. One-third of females and two-thirds of males with thalassemia major fail to enter puberty after myeloablative treatment. Patients who are compliant with chelation have 50% chance of being alive at 30 y, whereas for noncompliant patients, this rate is 10%. Transmission of viral infections, especially HIV, hepatitis B, and hepatitis C remains an important complication.

Iron chelation is recommended for children >2 y after >10 transfusions, serum ferritin >1,000 $\mu\text{g/L}$ (2,247 pmol/L), or liver iron ≥ 3 mg/g dry weight liver. The goals of chelation are liver iron 3 to 7 mg/g dry weight liver, ferritin 1,000 ng/mL (2,247 pmol/L), cardiac T2* >20 ms, and avoidance of organ dysfunction caused by iron overload. With aggressive chelation, iron-induced cardiotoxicity can be reversed and some endocrine complications may be improved. It is necessary to monitor for the adverse effects of chelation therapy with monthly liver and kidney function tests as well as annual audiologic and vision screening.

VII. Neonatal hematology

Hemoglobin F does not bind to 2,3-bisphosphoglycerate (2,3-BPG), accounting for its high oxygen affinity compared to hemoglobin A. This physical property allows hemoglobin F to bind more oxygen. Hemoglobin F is also more easily oxidized to methemoglobin (unable to bind oxygen as

the iron in the heme is ferric [Fe³⁺] rather than ferrous [Fe²⁺]. Cells rich in hemoglobin F are larger and more resistant to osmotic stress than adult red cells. Thus, the diagnosis of hereditary spherocytosis utilizing osmotic fragility test should be delayed until after 6 mo.

Anemia of prematurity occurs in infants ≤ 32 weeks' gestation. The hemoglobin reaches nadir at 4 to 8 weeks, as compared to the physiologic anemia of full-term newborns at 8 to 12 weeks. Its etiology includes low erythropoietin secretion and frequent phlebotomy. Prevention includes: (1) delayed cord clamping (30 to 60 sec), (2) reducing phlebotomy, (3) providing iron, and (4) increasing protein intake (3 to 4 g/kg/day).

Alloimmune hemolytic disease of the newborn (erythroblastosis fetalis) is a severe hemolysis caused by maternal anti-D (in Rh D negative mother) against D antigen (in Rh D positive fetus). Maternal anti-Kell is the second most common. Severity of the anti-Kell disease may progress quickly due to antibody-mediated suppression to erythropoiesis. Maternal antibodies against Duffy and the c and E antigens in the Rh group can also cause severe hemolysis. These infants are at risk for hyperbilirubinemia (kernicterus). Infants of these mothers may require an exchange transfusion if the bilirubin level is concerning. If the disorder is identified in utero, intrauterine transfusion may be utilized. IgG is not beneficial. Patients must be followed closely because anemia may be lasting. The primary approach to RhD incompatibility is

prevention; an RhD-negative mothers should receive one dose of anti-RhD at 28 weeks' gestation and again postnatally. Hemolytic disease of the newborn caused by ABO incompatibility occurs exclusively in association with type 'O' mothers and type 'A' or 'B' mother; it is usually mild.

Hereditary spherocytosis {spherocytosis type 1; *SPH1* (MIM#182900, AD); *ANK1* (MIM#612641, ankyrin 1); *SPH4* (MIM#612653, AD); *SLC4A1* (MIM#109270, solute carrier family 4, anion exchanger, member 1)} is a heterogeneous defect in the red cell cytoskeleton, most commonly due to abnormal spectrin. It is sporadic in 10% of the cases. The defect results in membrane (surface) loss, causing sphere-shaped cells, increased fragility and premature trapping in the spleen. The presence of spherocytes on the blood smear establishes the diagnosis. Hemolysis may begin in the first 24 h of life, causing neonatal jaundice. Hypoplastic episodes (severe anemia and reticulocytopenia) due to a viral infection (e.g., B19 parvovirus) are common. Blood transfusion may be necessary during acute hemolytic or hypoplastic episodes. Splenectomy is necessary for persistent hemoglobin < 100 g/L and reticulocyte count $> 10\%$. In neonates, eosin-5'-maleimide (EMA) is more reliable than peripheral smear (as neonatal erythrocyte morphology has significant variation) or osmotic fragility. Eosin-5'-maleimide binding is influenced by the MCV; thus, neonatal references (with a typical MCV of 105 fL) are needed to interpret the results. In a patient with a classic presentation and typical spherocytes on peripheral smear, particularly with a positive family history, no further diagnostic testing is required. Otherwise, a combination of eosin-5'-maleimide-binding and acidified glycerol reliably identifies hereditary spherocytosis, particularly in mild disease.

Hereditary elliptocytosis (HE) describes peculiar red cells with micropoikilocytes, elliptocytes, budding, and fragmentation. It is caused by pathogenic variants in the red cell membrane cytoskeletal proteins (e.g., α -spectrin, β -spectrin, protein 4.1R, glycophorin C). Its four types are: (1) Common HE; (2) Hemolytic HE; (3) Hereditary poikilocytosis/pyknocytosis (HPP); and (4) Spherocytic elliptocytosis (SE). Common HE (autosomal dominant) shows elliptocytes on blood smear in asymptomatic child (a mild hemolysis may occur with illnesses). Affected neonates may have severe hemolysis. Splenectomy may be required in HPP to improve the anemia; the MCV is typically very low (30 to 50 fL). SE is characterized by elliptocytes and microspherocytes (without poikilocytosis or fragments).

Neonatal alloimmune thrombocytopenia results from maternal antibodies against human platelet antigen (HPA, most commonly HPA-1a followed by

HPA-5b and HPA-15b) that is present in the fetus and not in the mother. It can occur in the first pregnancy. The thrombocytopenia is often severe and may result in intracranial bleeding. Maternal platelet apheresis is effective. Other causes include maternal immune thrombocytopenia (ITP), asphyxia, pregnancy-induced hypertension, intrauterine growth retardation, viral infection (cytomegalovirus), sepsis, and trisomy 21.

About 10% of infants of mothers with ITP develop thrombocytopenia, which may occur after the mother's platelet count is normalized. The clinical presentation is less severe than in 'neonatal alloimmune thrombocytopenia'. The risk of intracranial hemorrhage is low and is not influenced by the mode of delivery. Platelet counts need to be checked from a cord blood sample and repeated every 2-3 days for the first week. Platelet counts usually reach a nadir in 2 to 5 days and recover by day 7; some infants remain thrombocytopenic for 3 mo. Cranial ultrasonography should be performed to assess intracranial hemorrhage. Infants with a platelet count of $< 50 \times 10^6/L$ or with a clinical bleeding should be treated with intravenous immunoglobulin (1 g/kg/day for 2 days) plus corticosteroids. Platelet transfusion may be used for severe cases.

Newborns whose mothers have systemic lupus erythematosus (SLE) frequently develop skin lesions (erythematous, annular) and complete atrioventricular block. Mothers with Ro/SSA and La/SSB autoantibodies are more likely to have a newborn with lupus syndrome. The resulting anemia and thrombocytopenia respond to transfusion, corticosteroids and intravenous immunoglobulin. The neutropenia resolves by 6 mo [?].

Trisomy 21 is frequently associated with lymphopenia, abnormal thymus development and function, frequent respiratory infections, autoimmunity, and hematologic malignancy. The newborn screening for *severe combined immune deficiency (SCID)* is through identification of *T-cell receptor excision circles (TREC)*.

Severe congenital neutropenia is a heterogeneous disorder associated with neutrophil counts $< 0.2 \times 10^9/L$ from birth, myeloid arrest at the promyelocyte/myelocyte stage and recurrent infections. These infants have increased risk of myelodysplasia and acute myelogenous leukemia (AML). The use of granulocyte colony-stimulating factor (G-CSF) increases the risk of AML. In one study, there was a 5.7 higher risk of myelodysplasia/AML in children who received G-CSF at 15 $\mu\text{g/kg}$ per day, compared with those who received no or lower G-CSF dose. The estimated hazard risk is 2% per year. Thus, G-CSF is given only for a specific infection. *ELANE* (elastase, neutrophil-expressed, MIM#130130) variants are seen in both severe congenital neutropenia (MIM#202700, autosomal dominant) and cyclic neutropenia (MIM#162800, autosomal dominant). *Shwachman syndrome* (*gene*: ribosome maturation factor, SBDS, MIM#607444; *phenotype*: MIM#260400, autosomal recessive) is associated with pancreatic malabsorption, bell-shaped chest, metaphyseal dysplasia, and waxing and waning neutropenia.

Neonatal alloimmune neutropenia occurs with maternal sensitization to fetal neutrophils bearing paternal antigens; more common in multiparous mothers. It may last up to 6 mo. The bone marrow shows myeloid hyperplasia. The antibody is identified in the serum of the mother and the infant, and is against the HNA-1 neutrophil FC γ receptor IIIB.

Benign (ethnic, familial) neutropenia is mild and associated with African, Yemenite, West Indian, and Arab ancestries. It is linked to variants in *ACKR1* (atypical chemokine receptor 1; MIM#613665); previously termed: Duffy antigen receptor for chemokines (*DARC*).

References

1. Denic S, Souid AK, Nicholls MG. The Automated Blood Count: Its History, Utility and Need for Change. J Community Med Health Educ 2019; 9: 671.

2. Prentice AM. Clinical implications of new insights into hepcidin-mediated regulation of iron absorption and metabolism. *Ann Nutr Metab.* 2017;71 Suppl 3:40-48.
3. Repo M, Lindfors K, Mäki M, Huhtala H, Laurila K, Lähdeaho ML, Saavalainen P, Kaukinen K, Kurppa K. Anemia and iron deficiency in children with potential celiac disease. *J Pediatr Gastroenterol Nutr.* 2017;64:56-62.
4. Shahriari M, Honar N, Yousefi A, Javaherizadeh H. Association of potential celiac disease and refractory iron deficiency anemia in children and adolescents. *Arq Gastroenterol.* 2018;55:78-81.
5. Powers JM, Shamoun M, McCavit TL, Adix L, Buchanan GR. Intravenous ferric carboxymaltose in children with iron deficiency anemia who respond poorly to oral iron. *J Pediatr.* 2017;180:212-216.
6. Conway M, Marcon P, Meinert P, Durno C, Upton JEM, Kirby-Allen M, Weinstein M. A toddler with treatment-resistant iron deficiency anemia. *Pediatrics* 2018;142:e20172971.
7. De Caterina M, Grimaldi E, Di Pascale G, Salerno G, Rosiello A, Passaretti M, Scopacasa F. The soluble transferrin receptor (sTfR)-ferritin index is a potential predictor of celiac disease in children with refractory iron deficiency anemia. *Clin Chem Lab Med.* 2005;43:38-42.
8. Camaschella C. New insights into iron deficiency and iron deficiency anemia. *Blood Rev.* 2017;31:225-233.
9. Girelli D, Ugolini S, Busti F, Marchi G, Castagna A. Modern iron replacement therapy: clinical and pathophysiological insights. *Int J Hematol.* 2018;107:16-30.
10. Low MS, Grigoriadis G. Iron deficiency and new insights into therapy. *Med J Aust.* 2017;207:81-87.
11. Amin SB, Orlando M, Wang H. Latent iron deficiency in utero is associated with abnormal auditory neural myelination in ≥ 35 weeks gestational age infants. *J Pediatr.* 2013;163:1267-1271.
12. De-Regil LM, Jefferds ME, Sylvetsky AC, Dowswell T. Intermittent iron supplementation for improving nutrition and development in children under 12 years of age. *Cochrane Database Syst Rev.* 2011;12:CD009085.



This work is licensed under Creative Commons Attribution 4.0 License

To Submit Your Article Click Here: [Submit Manuscript](#)

DOI: [10.31579/2692-9392/195](https://doi.org/10.31579/2692-9392/195)

Ready to submit your research? Choose Auctores and benefit from:

- ❖ fast, convenient online submission
- ❖ rigorous peer review by experienced research in your field
- ❖ rapid publication on acceptance
- ❖ authors retain copyrights
- ❖ unique DOI for all articles
- ❖ immediate, unrestricted online access

At Auctores, research is always in progress.

Learn more www.auctoresonline.org/journals/archives-of-medical-case-reports-and-case-study